Personalized mRNA Vaccine Cuts Melanoma Recurrence Risk in Phase 3 Trial

A Phase 3 trial presented at ESMO 2026 found that adding a personalized mRNA vaccine to Keytruda after melanoma surgery lowered the risk of the cancer returning. Overall survival has not yet differed significantly, and the full peer-reviewed paper is still to come.